Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national ...

New podcasts from advocacy organization Phaware will highlight treatment advances in pulmonary hypertension tied to ...

ShareChronic diseases like diabetes, hypertension, cancer, and chronic obstructive pulmonary disease (COPD) affect millions ...

Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with PAH.

A small, multi-country analysis of women of child-rearing age has found that these patients experience limits on activities ...

Access to a webcast of the presentation will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an ...

In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...

Main pulmonary artery diameter is a prognostic indicator in patients with pulmonary arterial hypertension without congenital heart disease.

Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until it was removed from the market in 1997 after valvular heart damage and pulmonary hypertension were found.

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a cardiologist and learned that I had mild to moderate mitral stenosis with ...